PALLIATIVE TREATMENT BY DR. KHRONGKAMOL SIHABAN MEDICAL ONCOLOGIST

Similar documents
Palliative Prescribing - Pain

Opioid Conversion Guidelines

Pain Management Strategies Webinar/Teleconference

GUIDELINES ON THE MANAGEMENT OF PAIN DUE TO CANCER IN ADULTS

GUIDELINES AND AUDIT IMPLEMENTATION NETWORK

Opioid Case Studies. Thomas P. Pittelkow, D.O., M.P.H. Mayo Clinic College of Medicine Rochester, MN. September 29, MFMER slide-1

1/21/14. Cancer Related Pain: Case-Based Pharmacology. Conflicts of Interest. Learning Objective

Pain Management in Hospice and Palliative Care

Optimizing Your Quality of Life During Cancer Treatment: Pain & Side Effect Management

Review of Pain Management with Clinical and Regulatory Updates

Overview of Essentials of Pain Management. Updated 11/2016

Equianalgesic Dosing: Making Opioid Interchange Easier. Joseph Bubalo PharmD, BCPS, BCOP Oncology Clinical Pharmacist Assistant Professor Of Medicine

Analgesia. This is widely used in palliative care. It has antipyretic and analgesic effects but no anti-

Pain management. Coleman Palliative Care Conference: February 2016 Josh Baru MD Stacie Levine MD

Narcotic Analgesics. Jacqueline Morgan March 22, 2017

Management of Cancer Pain

Opioid Pearls and Acute Pain Management

FDA hormone replacement therapy Web site 6

Long Term Care Formulary HCD - 08

GG&C Chronic Non Malignant Pain Opioid Prescribing Guideline

Pain management in Paediatric Palliative Care. Dr Jane Nakawesi 14 th August 2017

Dose equivalent of fentanyl patch to oxycontin

Opioid Rotation. Dr Bruno Gagnon, M.D., M.Sc.

10 mg hydrocodone equals how much oxycodone

Interprofessional Webinar Series

RELIEVING VIRGINIA S PAIN AND SUFFERING 3:45-4:45PM

PAIN. TREATMENT TABLES Analgesics. NON-OPIOID ANALGESICS Generic Name Trade Names (Examples) Duration Initial Dose

Mitigating Risks While Optimizing the Benefits of Pharmacologic Agents to Manage Pain in the Elderly

Drug Information Common to the Class of Extended-Release and Long-Acting Opioid Analgesics (ER/LA opioid analgesics) Avinza Butrans

Palliative Care for Primary Care Providers QUYNH BUI, MD MPH DECEMBER 2015

Opioid Conversions Mixture of Science and Art

Palliative and Hospice Care of the Terminally Ill Introduction

Pain is a more terrible Lord of mankind than even death itself.

Cancer Pain: A Clinical Overview. Linda A. King, MD Section of Palliative Care and Medical Ethics

Analgesics: Management of Pain In the Elderly Handout Package

E-Learning Module N: Pharmacological Review

Fighting the Good Fight: How to Convert Opioids Just Right!

Module 2 Pain Management. Handouts. Pain Is... Please click the links button under the video. You can print and/or save the handouts.

PAIN MANAGEMENT COMPETENCY

Pancreatic cancer Palliative Care

THE EAPC OPIOID GUIDELINES: PROCESS, RESULTS AND FUTURE DEVELOPMENT

Pain Management in the Hospital

B. Long-acting/Extended-release Opioids

Managing Care at End of Life:

BASICS OF OPIOID PRESCRIBING 10:30-11:45AM

Slide 1. Slide 2. Slide 3. Opioid (Narcotic) Analgesics and Antagonists. Lesson 6.1. Lesson 6.1. Opioid (Narcotic) Analgesics and Antagonists

Supporting Last Days of Life Symptom Control Medication Guidance: Algorithm. Agitation & Anxiety

Opioid Use in Serious Illness

Po dilaudid versus iv dilaudid

Q&A: Opioid Prescribing for Chronic Non-Malignant Pain

Oxymorphone (Opana ) is indicated for the relief of moderate-to-severe acute pain where the use of an opioid is appropriate.

15mg oxycodone is equivalent to how much morphine

Berkshire West Area Prescribing Committee Guidance

Objectives: What is your Definition of Pain? 8/16/2017

Knock Out Opioid Abuse in New Jersey:

HOPE. Considerations. Considerations ISING. Safe Opioid Prescribing Guidelines for ACUTE Non-Malignant Pain

Acute Pain Management in the Hospital Setting. Alexandra Phan, PharmD PGY-1 Pharmacy Practice Resident Medical Center Hospital Odessa, TX

Pain and Chemical Dependency Fathy Nasr

Amber D. Hartman, PharmD Specialty Practice Pharmacist James Cancer Center & Solove Research Institute Ohio State University Medical Center

Session II. Learning Objectives for Session II. Key Principles of Safe Prescribing. Benefits and Limitations of ER/LA Opioids

PAIN MANAGEMENT PGY-1. Aaron D. Storms, MD Carin van Zyl, MD Adult and Pediatric Palliative Care, LAC+USC Keck School of Medicine of USC

PAIN MANAGEMENT Patient established on oral morphine or opioid naive.

Pain management in palliative care. Dr. Stepanie Lippett and Sister Karen Davies-Linihan

Pain control in Cancer patients. Dr Ali Shoeibi, Assistant Professor of Neurology

PRESCRIBING GUIDELINES FOR SYMPTOM MANAGEMENT IN THE DYING PATIENT

SCOPING DOCUMENT FOR WHO Treatment Guidelines on pain related to cancer, HIV and other progressive life-threatening illnesses in adults

Conversion chart from fentanyl to opana er

J Clin Oncol 23: by American Society of Clinical Oncology INTRODUCTION

NATL. II. Health Net Approved Indications and Usage Guidelines: Diagnosis of cancer AND. Member is on fentanyl transdermal patches AND

NOVIDADES NO TRATAMENTO COM OPIOIDES. Novelties in therapeutic with opioids. V Congresso National de Cuidados Palliativos Marco 2010, Lisboa

The pain of it all. Rod MacLeod MNZM. Hibiscus Hospice, Auckland and University of Auckland

Opioid Pharmacology. Dr Ian Paterson, MA (Pharmacology), MB BS, FRCA, MAcadMEd. Consultant Anaesthetist Sheffield Teaching Hospitals

BJF Acute Pain Team Formulary Group

For patients and their carers this means smoother symptom control, better support in a crisis, and avoidance of admission if that is their choice.

2017 Opioid Prescribing Module 401 N. Ewing St. Lancaster, Ohio (740) ~

Opioid Analgesics. Recommended starting dose for opioid-naïve patients

Mid Essex Locality Guideline for Management of Adult Acute and Chronic Non-Cancer Pain in Primary care

Pain Management Management in Hepatic Hepatic and and Renal Dysfunction

Cancer Pain. Suresh K Reddy, MD,FFARCS The University of Texas MD Anderson Cancer Center

Nociceptive Pain. Pathophysiologic Pain. Types of Pain. At Presentation. At Presentation. Nonpharmacologic Therapy. Modulation

Postoperative Pain Management. Nimmaanrat S, MD, FRCAT, MMed (Pain Mgt)

Narcotic Equivalence Converter Narcotic Route Dose Duration; Select a drug: mg Convert to: mg Adapted from Tarascon Pocket Pharmacopoeia.

Opioid rotation or switching may be considered if a patient obtains pain relief with one opioid and is suffering severe adverse effects.

Management of Cancer Pain

Sharon A Stephen, PhD, ARNP, ACHPN. September 23, 2014

Chronic Non Malignant Pain Opioid Guideline

PAIN MANAGEMENT 101. By: Vicki McCulloch RN, NP & DeAnna Looper RN, CHPN, CHPCA

Overcoming challenges in pain management in older patients. David Lussier, MD, FRCP(c) March 21, 2012

Pharmacogenetics of Codeine. Lily Mulugeta, Pharm.D Office of Clinical Pharmacology Pediatric Group FDA

Drugs Used In Management Of Pain. Dr. Aliah Alshanwani

Lumbar Fusion. Reference Guide for PACU CLINICAL PATHWAY. All patient variances to the pathway are to be circled and addressed in the progress notes.

PAIN MANAGEMENT Person established taking oral morphine or opioid naive.

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

WR Fentanyl Symposium. Opioids, Overdose, and Fentanyls

15 mg morphine 10 mg hydrocodone

OPIOIDS: THE GOOD, THE BAD, AND EVERYTHING IN-BETWEEN

Long-Acting Opioid Analgesics

Opioids: Use, Abuse and Cause of Death. Jennifer Harmon Assistant Director - Forensic Chemistry Orange County Crime Laboratory

Acute pain management in opioid tolerant patients. Muhammad Laklouk

OPIOID- INDUCED NEUROTOXICITY*

Transcription:

PALLIATIVE TREATMENT BY DR. KHRONGKAMOL SIHABAN MEDICAL ONCOLOGIST

TREATMENT IN ONCOLOGY Main treatment : surgery Neoadjuvant treatment : RT, CMT Adjuvant treatment : Tx micrometastatic disease -CMT,Targeted therapy -RT -Hormone

TREATMENT IN ONCOLOGY Palliative treatment : quality of life, prolong life, relieve symptom -CMT, Targeted therapy -RT -Sx -Others -BSC

Treatment outline of early or locally advanced cancer Early or locally advanced cancer Primary treatment: surgery Neoadjuvant chemotherapy/ radiotherapy Adjuvant chemotherapy / radiotherapy Unresectable Surveillance Recurrent disease In remission

Treatment outline of advanced or metastatic cancer Advanced or metastatic cancer Resectable Unresectable Surgery Postoperative Chemotherapy/ radiotherapy Palliative chemotherapy/ radiotherapy Response Second-line Not response/ Too toxic Best supportive care

ASSESSMENT BY ONCOLOGY TEAM Benefits/Burdens of anticancer therapy - Natural of specific tumor - Potential for response to further treatment - Potential for treatment-related toxicities - Patient s understanding of disease prognosis - Goal and meaning of anticancer therapy for patient/family/caregivers - Impairment of vital organs - Performance status - Serious comorbid conditions

ASSESSMENT BY ONCOLOGY TEAM Patient/family/caregivers goals/values/expectations/priorities - Shared decision-making with patient/family/caregivers - Advance care planning - Goals and meaning of anticancer therapy - Quality of life

ASSESSMENT BY ONCOLOGY TEAM Symptom management - Pain - Dyspnea - Anorexia/cachexia - Nausea/vomiting - Constipation - Diarrhea - Etc.

DOMAINS FOR PAIN MANAGEMENT OUTCOME : 4 A s Analgesia Activities of Daily Living Adverse Events Aberrant Drug-Taking Behaviors

CANCER PAIN MANGEMENT STRATEGIES Pharmacologic strategies - Nonopioid analgesics - Acetaminophen - Nonsteroidal anti-inflammatory drugs - Opioid analgesics - Coanalgesics (adjuvant analgesics) Psychological strategies - Hypnosis or relaxation with imagery - Cognitive-behavioral methods

CANCER PAIN MANGEMENT STRATEGIES Physical strategies - Massage - Exercise - Transcutaneous electrical nerve stimulation (TENS) - Acupucture Nerve blocks Radiation therapy Chemotherapy

OPIOID ANALGESICS : CANCER PAIN Used most often in the management of severe pain : - Effectiveness - Ease of titration - Favorable risk-to-benefit ratio Routes of administration - Oral - Transdermal - Intraspinal : epidural or intrathecal

OPIOID FORMULATIONS TYPE OF DRUG Pure µ-opioid receptor agonists Dual mechanism opioids Rapid onset (transmucosal) Immediate release Modified release (long acting) Available with co-analgesic Only available with co-analgesic EXAMPLES Morphine, hydromorphone, fentanyl, oxycodone Tramadol, tapentadol Fentanyl, alfentanil, sufentanil, diamorphine Tramadol, oxycodone Morphine, methadone, oxycodone Oxycodone, tramadol, codeine Hydrocodone

Codeine natural opioid ADR : Constipation Onset Duration Dosage Ceiling dose Shift when 30 mins 4-6 hrs 30 60 mg PO q 4-6 hrs 120 mg/dose not response at 60 mg q 4 hrs

Tramadol synthetic opioid Action: MOPr and SNRI ADR : N/V, Dizziness Onset Duration 1 hr 8 hrs Dosage Ceiling dose Shift when 50 100 mg PO q 6-8 hrs 100 mg/dose not response at 400 mg/day

Morphine natural opioid Injection Oral Immediate release Controlled release Onset : IV < 5 mins MO IR 15 30 min MST 1 hr Kapanol 2-4 hr PotencyOral = 1/3 IV (1 st pass metabolism effect) Sustained release MST 10, 30 mg Extended release Kapanol 20, 50 mg

Oxycodone semisynthetic opioid Onset 15 min for IR, Stable over 12 hr for CR Initial dose 5 15 mg PO q 4-6 h (IR) 10 mg PO q 12 h (CR) Dosage 10-30 mg PO q 4-6 h (titrate up 25% q 12 hr for CR)

Fentanyl synthetic opioid Highly lipid soluble Onset Duration Prep. 12-24 hrs 72 hrs/patch 12, 25, 50 mcg/hr Initiation Naïve to opioid 12 25 mcg/hr Do not forget to prescribe bridging analgesics in first 12-24 hr

ADVERSE DRUG REACTION OF OPIOID ANALGESIC DRUGS

Skin Neuro GI ADVERSE REACTION of opioids usage Sedation Confusion Myoclonus Respiratory depression Nausea / Vomiting Constipation Itching Histamine release Dry lips Urinary retention

NEUROLOGICAL ADR of opioids usage Sedation Confusion Myoclonus Reduce 25% Methylphenidate IR Light Exposure T Reduce 25 % TCA LT ADR Baclofen, Valium Respiratory depression Naloxone 0.2 mg IV push q 2-3 min Dry mouth NaHCO 3 mouthwash 3-4 times/day T Urinary retention Foley s cath T. T = Tolerable ADR

GASTROINTESTINAL ADR of opioids usage Nausea / Vomiting Co-administration antiemetics Constipation Stimulant laxative Stool softener *** AVOID bulk forming *** T T = Tolerable ADR

OPIOID SWITCHING Opioid rotation ( or switching) is a change in opioid drug or route of administration with the goal of improving outcomes. Opioid therapy for acute or chronic pain requires individualization of the dose, with the objective of identifying a favorable balance between analgesia and side effects.

INDICATIONS FOR SWITCHING Occurrence of intolerable adverse effects during dose titration Poor analgesic efficacy despite aggressive dose titration Problematic drug-drug interactions Preference or need for a different route of administration Change in clinical status (e.g. concern about drug abuse) or clinical setting that suggests benefit from an opioid with different pharmacokinetic properties Financial or drug-availability considerations

STEP 1 : EFFICACY OPIOID ROTATION Calculate Equianalgesic dose (the dose in steady state provide the same analgesic response) Require special consideration MO (PO) MO (IV) Oxycontin Codeine Tramadol Fentanyl TTS Methadone IV 30 mg 10 mg 15 mg 200 mg 250 mg 12 mcg/hr 8 mg Methadone Oral 16 mg 1 x 1.5 x 20 x 25 x 1.2 x 0.8 x 3 1 1 x 2.

STEP 2 : SAFETY Pathogenesis : Variation of MOPr subtype in different person Identified Automatic Dose Reduction Windows ~ 25 50 % due to incomplete cross-tolerance 25 % in General population 50 % in currently on High dose Elderly/Frailty

STEP 3 : INDIVIDUALIZED Re-assessment Titration up 25% if inadequate Rescue dosing prescription 10 15 % (1/6 of total daily dose)

EXAMPLE A 56 years old female who has advance stage CA breast which currently on Kapanol (50) 2 tab PO at 8PM MST (10) 2 tab PO at 8AM MO IR (10) 2 3 tab per day Kapanol was sold out from hospital. So you need to change it to another drugs

EXAMPLE Step 1: Calculate MEDD [(100+20) 3] + [10x3 3] 40 + 10 50 mg of MO IV per day Step 2 : calculate ADRW

EXAMPLE Switch to Oxycontin 37.5 x 1.5 = 56.25 mg Order Oxycontin (30) 1 tab PO q 12 h

EXAMPLE Step 3: Breakthrough : 6.25 mg MO IR (10) 1 tab PO prn q 4-6h Reassessment If not adequate +25% (~9-10 MO equivalence)

Jirawat Thanestada, M.D. SUMMARY